For inquiries or customized services, please reach us at Info@pharmaceutical-era.com
The ESMO TAT Congress 2027 is a leading international meeting for early‑phase clinical development and translational research in targeted therapies.
Bringing together global experts from academia, clinical practice and industry, the congress offers an in‑depth look at emerging anticancer agents, novel combinations and biomarker‑driven strategies that are transforming outcomes for patients with cancer.
For academic researchers and clinicians
ESMO TAT 2027 is the place to discuss hypothesis-generating data, explore innovative trial designs and understand how emerging agents fit into evolving treatment pathways.
Oncologists, clinicians, scientists, translational researchers, pharmacologists, and statisticians will find a programme tailored to the realities of early phase development in routine practice.
From mechanism of-action to first-in-human dosing, from biomarker selection to resistance and toxicity management, the congress supports you in bringing promising new options to patients more efficiently and safely.
| Event Date | 22 Feb 2027 |
| Event End Date | 24 Feb 2027 |
| Organizer | ESMO |
| Location | France |